{
    "organizations": [],
    "uuid": "2991c5445d59b55f3c44437d8992dcac8831c963",
    "author": "",
    "url": "https://www.reuters.com/article/brief-nymox-reports-5-yr-results-from-pr/brief-nymox-reports-5-yr-results-from-prostate-cancer-study-of-fexapotide-triflutate-in-146-u-s-men-idUSFWN1PH10X",
    "ord_in_thread": 0,
    "title": "BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 22, 2018 / 7:00 PM / Updated 2 minutes ago BRIEF-Nymox Reports 5-Yr Results From Prostate Cancer Study Of Fexapotide Triflutate In 146 U.S. Men Reuters Staff 1 Min Read \nJan 22 (Reuters) - Nymox Pharmaceutical Corp: \n* NYMOX REPORTS 5-YEAR RESULTS FROM PROSPECTIVE RANDOMIZED CONTROLLED PROSTATE CANCER STUDY OF FEXAPOTIDE TRIFLUTATE IN 146 U.S. MEN \n* NYMOX - HIGH DOSE FEXAPOTIDE 15MG SINGLE DOSAGE TREATMENT RESULTED IN 80% LESS SURGERY OR RADIOTHERAPY ASSOCIATED WITH GLEASON GRADE PROGRESSION \n* NYMOX PHARMACEUTICAL CORP - STUDY ALSO SHOWED THAT BOTH DOSES OF FEXAPOTIDE WERE CONSISTENTLY EFFECTIVE Source text for Eikon: Further company coverage:",
    "published": "2018-01-22T20:59:00.000+02:00",
    "crawled": "2018-01-22T21:13:11.010+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "updated",
        "minute",
        "ago",
        "report",
        "result",
        "prostate",
        "cancer",
        "study",
        "fexapotide",
        "triflutate",
        "men",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "nymox",
        "pharmaceutical",
        "corp",
        "nymox",
        "report",
        "result",
        "prospective",
        "randomized",
        "controlled",
        "prostate",
        "cancer",
        "study",
        "fexapotide",
        "triflutate",
        "men",
        "nymox",
        "high",
        "dose",
        "fexapotide",
        "15mg",
        "single",
        "dosage",
        "treatment",
        "resulted",
        "less",
        "surgery",
        "radiotherapy",
        "associated",
        "gleason",
        "grade",
        "progression",
        "nymox",
        "pharmaceutical",
        "corp",
        "study",
        "also",
        "showed",
        "dos",
        "fexapotide",
        "consistently",
        "effective",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}